BJMO - volume 12, issue 3, february 2018
D. Verhoeven MD, PhD
Quality management is a key requirement to obtain the best care for patients. In previous years, a lot of effort was made in defining quality indicators for breast cancer in Belgium. Based on EUSOMA guidelines and in collaboration with several partners, a set of quality indicators of systemic breast cancer therapy were defined. These include structure indicators (e.g. education, day clinic facilities, etc.), outcome indicators (e.g. overall survival, disease-free survival, etc.) and process indicators. The first results of some of these process indicators were presented during the 2018 annual BSMO meeting.
Read moreBJMO - volume 12, issue 3, february 2018
F.P. Duhoux MD, PhD
In his presentation, professor François Duhoux (Cliniques Universitaires St. Luc, Brussels) gave an overview of the key messages from the 2017 San Antonio Breast Cancer Symposium. Four main topics were addressed: dose dense adjuvant chemotherapy, chemotherapy for patients with lobular disease, optimizing hormonal therapy for younger breast cancer patients and the optimal duration of endocrine therapy.
Read moreBJMO - volume 12, issue 3, february 2018
S. Aspeslagh
BJMO - volume 12, issue 3, february 2018
E. Seront MD, PhD
Multiple immune checkpoint inhibitors (ICIs) are currently available for the treatment of bladder cancer. The question raised by Dr Seront in his lecture was: “which agent should be used for which patient?”
Read moreBJMO - volume 12, issue 3, february 2018
L. Dirix MD
It has become a yearly tradition during the annual BSMO meeting to have a presentation by Dr Luc Dirix discussing the top stories in oncology over the past year. The 2018 edition was no exception.
Read moreBJMO - volume 11, issue 7, november 2017
P. Specenier MD, PhD
BJMO - volume 11, issue 7, november 2017
L. Triest MD, K. Papadimitriou MD, PhD, M. Rasschaert MD, J. Van den Brande MD, M. Peeters MD, PhD
ESMO 2017 featured the presentation of several practice changing data in the field of gastrointestinal (GI) cancer. The first part of this report will summarize the key data presented in the field of gastric cancer, gastroesophageal junction (GEJ), biliary, gallbladder, biliary, pancreatic and hepatocellular cancer. In the second part, the focus is turned to colorectal cancer.
(BELG J ONCOL 2017;11(7):340–348)
Read more
Top
